Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity

J Investig Med. 2022 Jan;70(1):3-4. doi: 10.1136/jim-2021-002227.

Authors

Ricardo Villela¹, Ricardo Correa²

Affiliations

¹ Deparment of Medicine, National Autonomous University of Honduras, Tegucigalpa, Francisco Morazán, Honduras.
² Department of Medicine, The University of Arizona College of Medicine - Phoenix and Phoenix VAMC, Phoenix, Arizona, USA riccorrea20@gmail.com.

PMID: 34949728
DOI: 10.1136/jim-2021-002227

No abstract available

Keywords: body weight; body weights and measures; glucagon-like peptide 1; obesity.

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptides / therapeutic use*
Humans
Hypoglycemic Agents
Obesity / drug therapy*

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
semaglutide
Glucagon-Like Peptides